Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

3 Feb 2021

Abstract excerpt

Hepatoblastoma (HB) is the most common pediatric liver malignancy. High-risk patients have poor survival, and current chemotherapies are associated with significant toxicities. Targeted therapies are needed to improve outcomes and patient quality of life. Most HB cases are TP53 wild-type; therefore, we hypothesized that targeting the p53 regulator Murine double minute 4 (MDM4) to reactivate p53 signaling may show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33536467
DOI: 10.1038/s41598-021-82542-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastomaPMID 33536467Read ↗

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity Read ↗

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?Semantic proximity Read ↗

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and ChallengesSemantic proximity Read ↗

Targeting the MDM2-p53 Interaction for Cancer TherapySemantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

MDM2: current research status and prospects of tumor treatmentSemantic proximity Read ↗

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancerSemantic proximity Read ↗

Ribonucleotide Reductase Subunit Switching in Hepatoblastoma Drug Response and RelapseSemantic proximity Read ↗

MDM2-p53 pathway in hepatocellular carcinoma.Semantic proximity Read ↗

Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastomaSemantic proximity Read ↗

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical TrialsSemantic proximity Read ↗

TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.